Drug Information and Pharmacotherapy

DI-001

ANALYSIS OF THE USE, EFFECTIVENESS AND SAFETY OF TREATMENT WITH TRASTUZUMAB-EMTANSINE IN METASTATIC BREAST CANCER

DI-094

TREATMENT OF PULMONARY EMPHYSEMA ASSOCIATED WITH ALPHA-1-ANTITRYPSIN DEFICIENCY

DI-093

PREDICTORS OF NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS

DI-092

POPULATION ATTRIBUTABLE RISK OF HIP FRACTURES IN ANTIDEPRESSANT USERS IN HUNGARY AND ESTIMATION OF THE RELEVANT COST CONSEQUENCES

DI-091

ASSESSMENT OF AN EDUCATION PROGRAM FOR PATIENTS TREATED WITH ORAL ANTICOAGULANTS IN A CARDIOLOGY DEPARTMENT: A PILOT STUDY

DI-089

EFFECTIVENESS OF ABIRATERONE IN PROSTATE CANCER IN CLINICAL PRACTICE

DI-088

SINGLE-TABLET REGIMEN TENOFOVIR/ EMTRICITABINE/ RILPIVIRINE: ONE YEAR'S EXPERIENCE

DI-087

SPONTANEOUS REPORTING OF ADVERSE DRUG REACTIONS IN A SECOND LEVEL HOSPITAL: IS PHARMACOVIGILANCE WELL TARGETED?

DI-086

INFLUENCE OF THE RECOMMENDATIONS OF THE EUROPEAN MEDICINES AGENCY REGARDING THE MODIFICATION OF THE PRESCRIPTION PATTERN OF METOCLOPRAMIDE

DI-085

EVOLUTION OF ANTIRETROVIRAL PRESCRIPTIONS IN TREATMENT-NAÏVE HIV-INFECTED PATIENTS

DI-084

COST-UTILITY OF SOFOSBUVIR-BASED TREATMENT FOR UNTREATED GENOTYPE 1 AND 3 HEPATITIS C PATIENTS

DI-083

AMPHOTERICIN B TOPICAL TREATMENT OF PLEURAL ASPERGILLOSIS: A CASE REPORT

DI-082

IMPROVEMENT IN THE LIPID PROFILE OF HIV-INFECTED PATIENTS AFTER SWITCHING TO RILPIVIRINE/EMTRICITABINE/TENOFOVIR

DI-081

ORAL CHEMOTHERAPY: INCIDENCE AND DESCRIPTION OF POTENTIAL INTERACTIONS BETWEEN DRUGS AND FOOD

DI-079

EFFECTIVENESS OF TREATMENT WITH IMMUNOGLOBULIN IN PATIENTS WITH ITP

Pages